Search This Blog

Wednesday, June 10, 2026

Sanofi halts Phase 3 of riliprubart in treatment-refractory CIDP; interim review finds low efficacy likely

 

Sanofi halts Phase 3 MOBILIZE trial of riliprubart in treatment-refractory CIDP after interim review finds low efficacy likelihood

  • Interim analysis concluded riliprubart was unlikely to meet primary efficacy endpoints in the Phase 3 MOBILIZE trial.
  • Sanofi expects no material financial impact from the MOBILIZE discontinuation and reaffirms its 2026 financial guidance.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)